Diadema Partners LP Neurocrine Biosciences Inc Transaction History
Diadema Partners LP
- $391 Billion
- Q3 2025
A detailed history of Diadema Partners LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Diadema Partners LP holds 37,754 shares of NBIX stock, worth $5.47 Million. This represents 1.36% of its overall portfolio holdings.
Number of Shares
37,754
Previous 94,042
59.85%
Holding current value
$5.47 Million
Previous $11.8 Billion
55.16%
% of portfolio
1.36%
Previous 3.6%
Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
724Shares Held
102MCall Options Held
230KPut Options Held
477K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...